Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758109 | 0.86 | MAOB (0.62) | MAOBMAOAPPARDRARARARB | |
| SCHEMBL5260336 | 0.85 | MAOB (0.62) | MAOBMAOAPPARD | |
| SCHEMBL21052036 | 0.84 | PPARD (0.74) | MAOBMAOAPPARD | |
| SCHEMBL2215253 | 0.84 | PPARD (0.55) | MAOBFFAR4FFAR1PPARDCYSLTR2 | |
| SCHEMBL8992391 | 0.82 | MAOB (0.58) | MAOBMAOARARARARB | |
| SCHEMBL9720060 | 0.82 | MAOB (0.58) | MAOBMAOARARARARB | |
| SCHEMBL3849764 | 0.82 | MAOB (0.61) | MAOBMAOAPPARDRARARARB | |
| SCHEMBL8760010 | 0.81 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL21098685 | 0.81 | CYSLTR2 (0.53) | FFAR4FFAR1PPARDCYSLTR2CYSLTR1 | |
| SCHEMBL14356128 | 0.80 | MAOB (0.66) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| CN-100384838-C | Novel benzylpiperidine compound | MITSUBISHI PHARMA CORP (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| CN-1505626-A | Novel benzylpiperidine compound | ������ҩ��ʽ���� | 2004-06-16 | — | — | CN | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-0689845-B1 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | AMERICAN CYANAMID CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5877296-A | REACTING DISULFIDE ANALOGS OF CALICHEAMICIN FAMILY WITH A CARRIER SUCH AS PROTEIN, PEPTIDE, MONO AND POLYCLONAL ANTIBODIES, THEIR ANTIGEN-RECOGNIZING FRAGMENTS AND CHEMICALLY OR GENETICALLY ENGINEERED COUNTERPARTS | AMERICAN CYANAMID COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5773001-A | ANTIGROWTH AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5767285-A | USEFUL FOR CONSTRUCTING DRUG CONJUGATES; ANTIBIOTIC ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5739116-A | DISULFIDE DERIVATIVE OF CALICHEAMICIN FAMILY; ANTITUMOR ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0689845-A2 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | AMERICAN CYANAMID COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | MAOB 2634/4885MAOA 3205/4885FFAR4 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.